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ABSTRACT
Clinical translation of the mixed-chimerism approach for inducing transplantation tolerance would be facilitated if
mobilized peripheral blood stem cells (mPBSCs) could be used instead of bone marrow cells (BMCs). Because the
use of mPBSCs for this purpose has not been investigated in nonmyeloablative murine protocols, we explored the
engraftment potential of mPBSCs in a CD45-congenic model as a first step. After 2, 1.5, or 1 Gy of total body
irradiation, CD45.1 B6 hosts received unseparated granulocyte colony-stimulating factor-mobilized CD45.2 B6
PBSCs or unseparated CD45.2 B6 BMCs. The same total cell numbers, or aliquots of mPBSCs and BMCs
containing similar numbers of c-kit cells, were transplanted both with and without a short course of rapamycin-
based immunosuppression (IS). Transplantation of mPBSCs induced long-termmultilineage macrochimerism, but
chimerism levels were significantly lower than among recipients of the same number of BMCs. Transplanting
aliquots containing similar numbers of c-kit cells reduced the difference between mPBSCs and BMCs, but lower
levels of chimerismwere nonetheless observed inmPBSC recipients. Chimerism levels correlatedmore closely with
the number of transplanted progenitor cells as determined by colony-forming unit assays. IS did not affect
chimerism levels, indicating that the donor CD45 isoform or other minor disparities do not pose a major barrier to
engraftment. Our findings indicate that under nonmyeloablative conditions, progenitor cells contained in mPBSCs
have an engraftment capacity similar to progenitor cells from BMCs, allowing induction of lasting mixed chimerism
with moderate cell numbers. On a cell-per-cell basis, unseparated BMCs have some advantages that may be
minimized if the number of progenitor cells is equalized. These results are expected to facilitate the development
of mPBSC-based allogeneic tolerance protocols.
© 2006 American Society for Blood and Marrow Transplantation
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Induction of donor-speciﬁc tolerance is a major re-
earch goal of transplantation medicine. Mixed chimer-
sm, established through the transplantation of donor
ematopoietic stem cells (HSCs), is an attractive toler-
nce strategy for clinical development [1]; however, a
ajor obstacle in the clinical translation of this approachs the required recipient conditioning. s
84Although mild conditioning protocols using co-
timulation blockers have been developed for the in-
uction of lasting allogeneic mixed chimerism using
elatively realistic bone marrow cell (BMC) doses (ap-
roximately 15  106 BMCs per mouse), they require
onmyeloablative total body irradiation (TBI) or cy-
otoxic drug treatment [2-5]. Many would still con-
ider such conditioning requirements too toxic for
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Nonmyeloablative Transplantation of Congenic PBSCs
Boutine use in organ transplant recipients. We and
thers have shown that allogeneic bone marrow trans-
lantation (BMT) can be achieved experimentally
ithout any cytoreductive conditioning if extremely
igh doses of BMCs are transplanted (approximately
00  106 BMCs per mouse) [6-9]. Although these
odels provide proof of principle that completely
oncytoreductive BMT regimens are possible, they
re not clinically practicable, because such high num-
ers of BMCs cannot be routinely obtained from a
ingle human donor.
In the clinic, the highest numbers of HSCs are
btained through the collection of mobilized periph-
ral blood stem cells (mPBSCs) from a living donor.
ransplantation of granulocyte colony-stimulating
actor (G-CSF)–mobilized PBSCs has an established
ole in the treatment of hematologic disease [10,11],
ith the cell yield of a mPBSC collection typically
eing 5- to 10-fold higher than that from a conven-
ional BM harvest from the iliac crests. However,
hile BM and mPBSC are used for similar clinical
ndications, they differ substantially with respect to
everal major biologic and immunologic characteris-
ics [12-16]. These differences are of concern as they
ould potentially inﬂuence the induction of mixed
himerism and tolerance in a signiﬁcant manner. In
articular, it is unknown whether co-stimulation
lockade retains the same tolerance-inducing effect if
llogeneic PBSCs are transplanted instead of BMCs.
Before investigating allogeneic mPBSCs in com-
ination with co-stimulation blockade, however, we
eemed it necessary to establish the behavior of mu-
ine mPBSCs after nonmyeloablative conditioning in
he absence of alloreactivity. For this purpose, we
ransplanted congenic mPBSCs after nonmyeloabla-
ive TBI.
Engraftment properties of murine PBSCs mobi-
ized with G-CSF and/or other growth factors have
een evaluated in lethally irradiated recipients, and
heir reconstituting capability has been established
17-24]. Although mostly allogeneic models were used
n these studies, congenic systems have been investi-
ated as well, albeit after myeloablative conditioning
22,24]. One study evaluated the graft-versus-leuke-
ia effect of allogeneic G-CSF–mobilized PBSCs af-
er 7 Gy of sublethal TBI, leading to high levels of
himerism ( 75%) [25]. The therapeutic effect of
ransplantation of a mixture of allogeneic and synge-
eic murine mPBSCs was demonstrated in a myeloa-
lative systemic lupus erythematosus–like autoim-
une disease model (BXSB) [19]. To the best of our
nowledge, however, murine mPBSCs have not yet
een investigated in detail after low-dose (1–3 Gy)
onmyeloablative TBI, and thus, their engraftment
roperties under these conditions remain unknown.
Consequently, although mPBSCs are an attractive
andidate for tolerance induction through co-stimula- ﬁ
B&MTion blockade and mixed chimerism due to the large
umber of hematopoietic cells obtainable from a sin-
le donor, nonmyeloablative or noncytoreductive mu-
ine protocols using mPBSCs have not been explored
or this purpose. As an initial step toward the devel-
pment of mPBSC-based mixed-chimerism protocols
or tolerance induction, we show here that CD45-
ongenic mPBSCs transplanted after nonmyeloabla-
ive TBI led to lasting multilineage mixed chimerism.
onsistent with the frequency of progenitor cells,
ransplantation of unseparated mPBSCs resulted in
igniﬁcantly lower levels of chimerism than transplan-
ation of the same number of unseparated BMCs, but
PBSC and BMC transplantation had a comparable
ngraftment efﬁciency per number of progenitor cells
ransplanted. These results should facilitate the develop-
ent of allogeneic mPBSC-based tolerance protocols.
ATERIALS AND METHODS
nimals
Female B6.SJL-PtprcaPep3b/BoyJ (CD45.1, hosts)
ere purchased from the Jackson Laboratory (Bar Har-
or, ME), and congenic female C57BL/6NCrl (B6:
-2b) mice (CD45.2, donors) were purchased from
he Charles River Laboratories (Sulzfeld, Germany).
nimals were kept under speciﬁc pathogen-free con-
itions and were used between 6 and 10 weeks of age.
ll experiments were approved by the local review
oard of the University of Vienna and were performed
n accordance with national and international guide-
ines for laboratory animal care.
MT and mPBSC Transplantation
CD45.1 hosts received nonmyeloablative TBI (2, 1.5
r 1 Gy, as indicated) 1 day before either mPBSC trans-
lantation or BMT. To avoid pooling of mPBSCs in
pleen, donor CD45.2 mice were splenectomized at
east 14 days before the mobilization procedure, as
escribed by Weissman et al. [22]. Thereafter, 5g of
uman G-CSF (approx. 250 g/kg; ﬁlgrastim, Neu-
ogen; Amgen Europe BV, Breda, The Netherlands)
ere injected subcutaneously for 5 consecutive days.
wo hours after the ﬁnal injection, the mice were
aximally bled (using tail bleeding and heart punc-
ure), and the heparinized blood was pooled and di-
uted with phosphate-buffered saline (PBS) (1:1). Sub-
equently, the same volume of 2% dextran T500
olution was added, to give a ﬁnal concentration of 1%
extran. Red blood cells were separated by sedimenta-
ion for 45 minutes at 37°C before the supernatant frac-
ion containing the mobilized leukocytes (mPBSCs) was
ollected. BM was harvested from tibiae, femura, and
umeri as described in detail previously [26]. Both
MCs and mPBSCs were ﬁltered through a 70-m
lter. BMCs were counted manually (by trypan blue
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2xclusion of dead cells), and mPBSCs were counted
oth manually and automatically. Cells were diluted
ith cold BM media (500 mL of Medium 199 [Sigma,
ienna, Austria], supplemented with 5 mL of HEPES
uffer [ICN; Biomedica, Vienna, Austria], 5 mg of
NAse [Sigma], and 2 mg of gentamycin [Sigma]), then
njected in a volume of 1 mL into a tail vein of recipient
ice (d0). BMCs and mPBSCs were used without fur-
her manipulation (without enrichment or depletion).
low Cytometric Analysis
Two-color ﬂow cytometric analysis was used to dis-
inguish donor and host cells of particular lineages, by
taining with ﬂuorescein isothiocyanate (FITC)-conju-
ated antibodies against CD4, CD8, B220, MAC-1,
K1.1, and biotin-conjugated CD45.2 (developed with
hycoerythrin-avidin). Mice were considered chimeric if
hey demonstrated at least 2% of donor cells within the
yeloid lineage and at least 1 lymphoid lineage. To
nalyze cell composition, BMCs and mPBSCs were
tained with FITC-conjugated antibodies against CD4,
D8, B220, MAC-1, CD117 (c-kit), CD49b, TCR-,
nd biotin-conjugated CD45.2 (developed with phy-
oerythrin-avidin). The percentage of subpopulations
mong CD45.2 live cells was calculated. Irrelevant
sotype controls were included, and propidium iodide
taining was used to exclude dead cells.
olony-Forming Unit Assay
BMCs and mPBSCs were suspended at a cell con-
entration of 1 106/mL in BM medium. In addition,
 105 of either BMCs or mPBSCs (in 100 L) were
ultivated in duplicates inside Petri plates (Falcon Nr.
003) with 1 mL of cultivating medium prepared by
ixing of 75 L of recombinant mouse IL-3 (25 ng/
L; R&D Systems, Minneapolis, MN) and 2.3 mL of
yeloCult H5100 medium (StemCell Technologies,
ancouver, BC, Canada). After 14 days of incubation,
olony-forming unit granulocytes/ macrophages
CFU-GM) were counted by an experienced hematol-
gist.
himerism in Transplanted Progenitor Cells
The total number of progenitor cells transplanted
er mouse was calculated by multiplying the number
f CFU colonies grown from 1 105 plated cells (288
or BMCs and 64 for mPBSCs) by 100 for BMCs
because 10  106 cells were transplanted) and by 300
or mPBSCs (because 30  106 cells were trans-
lanted). Accordingly, 28,800 progenitors per mouse
ere transplanted in the BMC group, and 19,200
rogenitors per mouse were transplanted in the
PBSC group. The level of chimerism per 1  104
ransplanted progenitor cells was then obtained by
ultiplying the measured percentage of donor chi-
erism (as determined by ﬂow cytometry [FCM]) by u
86 104 divided by the total number of transplanted
rogenitors (chimerism per 1  104 transplanted pro-
enitor cells  % measured chimerism  [1  104/
otal number of transplanted progenitors]). Thus, the
ercentage of measured chimerism was multiplied by
factor of 0.35 for BMCs (1 104/28,800) and by a
actor 0.52 for mPBSCs (1  104/19,200).
mmunosuppression
In the indicated groups, mice were injected with
mmunosuppressive drugs daily from day 0 to day 27.
rugs were used at following doses: rapamycin, 0.2
g/kg/day; methylprednisolone (MP), 10 mg/kg/day;
nd mycophenolate mofetil (MMF), 20 mg/kg/day.
rugs were diluted and administered as described
reviously [26]. Rapamycin was kindly provided by
yeth-Ayerst (Princeton, NJ), MMF was kindly pro-
ided by Roche (Vienna, Austria), and MP was pur-
hased from Aventis (Vienna, Austria).
tatistics
A 2-tailed Student t-test was used for comparing
himerism levels between groups. P values  .05 were
onsidered statistically signiﬁcant.
ESULTS
nseparated mPBSCs Successfully Engraft after
onmyeloablative Conditioning, Although with
educed Efficiency Compared with BMCs
Because to date only BMCs have been investigated
or the purpose of tolerance induction through non-
yeloablative hematopoietic stem cell transplantation
HSCT) and mixed chimerism, and because little is
nown about the engraftment properties of murine
PBSCs under nonmyeloablative conditions, the aim
f this study was to investigate the capability of “syn-
eneic” (ie, congenic) mPBSCs for the induction of
ixed chimerism after nonmyeloablative TBI. To
ompare the engraftment of mPBSCs and BMCs in
he absence of alloreactivity, we chose a CD45-con-
enic model. CD45.1 recipients received 2, 1.5, or 1
y TBI 1 day before transplantation of 20  106
nseparated mPBSCs or BMCs (6 mice per group).
All mice receiving either 20  106 mPBSCs or
MCs after 2, 1, or 1.5 Gy of TBI developed long-
erm multilineage macrochimerism (chimerism rates:
PBSC, 6/6, 6/6, 6/6; BMC, 6/6, 6/6, 6/6) (Figure 1).
himerism was stable for 29 weeks in all groups.
evels of chimerism obtained both with mPBSCs and
MCs were correlated with the dose of TBI. At all
ested TBI doses, mPBSC transplantation led to sig-
iﬁcantly lower levels of hematopoietic chimerism
ompared with those from transplantation of the same
umber of BMCs. For example, at the end of follow-
p, this difference (expressed as BMC vs mPBSC
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Nonmyeloablative Transplantation of Congenic PBSCs
Bhimerism after 2 Gy TBI) was 75% versus 31% for
D4 cells (P  .0005), 52% versus 16% for CD8
ells (P  .0005), 86% versus 44% for B cells (P 
0005), 75% versus 35% for myeloid cells (P .0005),
nd 63% versus 17% for NK cells (P  .0005); see
igure 1. Similar signiﬁcant differences were also ob-
erved in the groups treated with 1.5 and 1 Gy TBI.
We also determined chimerism levels in BM and
pleen (SPL) of randomly selected mice (2 per group,
t 1 Gy and 2 Gy TBI) at the end of follow-up (32
eeks posttransplantation); the results are given in
able 1. mPBSC recipients showed substantially
ower levels of chimerism compared with BMC recip-
ents (eg, in BM, 78% vs 42% for myeloid cells [P 
05] and 79% vs 40% for B cells [P  .005]; in SPL,
5% vs 29% for CD4 cells [P  .005], 59% vs 27%
or CD8 cells [P  .05], and 86% vs 47% for B cells
P  .05], using 2 Gy TBI).
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igure 1. Transplantation of PBSCs leads to signiﬁcantly lower
evels of long-term chimerism in comparison with BMT after non-
yeloablative TBI. CD45.1 mice (n  6/group) received either
0 106 CD45.2 BMC (A, B, C) or 20 106 CD45.2 mPBSCs (D,
, F) after various doses of TBI (2 Gy [A,D], 1.5 Gy [B, E], or 1 Gy
C, F). The percentages of donor-derived CD4 cells, CD8 cells,
cells, monocytes/granulocytes, and NK cells among white blood
ells were evaluated by FCM at different time points and are shown
s means. Levels of chimerism induced with mPBSCs were signif-
cantly lower than those induced with BMCs treated with the same
BI dose (A vs D, B vs E, and C vs F; P  .05). HSCT denotes
ematopoietic stem cell transplantation.FCM analysis of BMC and mPBSC composition p
B&MTevealed that, as expected, mPBSCs contained higher
ercentages of CD4 and CD8 cells (17% vs 2% for
D4 and 12% vs 2% for CD8 cells; Table 2) and
cells (39% vs 28%), but a lower percentage of
AC-1 cells (32% vs 65%), than BMCs. Of note,
he percentage of c-kit (CD117) cells was higher in
MCs than in mPBSCs (11.1% vs 3.7%).
The foregoing ﬁndings indicate that CD45-con-
enic mPBSCs can successfully engraft and induce
table long-term multilineage macrochimerism after
onmyeloablative TBI. Furthermore, the same num-
er of unseparated mPBSCs resulted in signiﬁcantly
ower chimerism levels compared with BMCs in all
ineages tested and at all 3 TBI doses used). The lower
ngraftment of unseparated mPBSCs was associated
ith a lower percentage of c-kit cells. These results
uggest a reduced per-cell potential of unseparated
urine mPBSCs to induce mixed chimerism under
onmyeloablative conditions.
he Chimerism Achieved with mPBSCs and
MCs Correlates with the Number of
ransplanted Progenitor Cells
The foregoing results suggest that the difference
n chimerism levels might be due to the higher per-
entage of c-kit cells in BMCs, implying a higher
umber of progenitors [27]. Consequently, we next
ransplanted aliquots of mPBSCs and BMCs contain-
ng similar numbers of c-kit cells. BMCs contain
pproximately 3 times as many c-kit cells as mPBSCs
11.1% vs 3.7%; Table 2), so based on this ratio, we
ransplanted 30 106 unseparated mPBSCs and 10
06 unseparated BMCs (with 1.5 Gy TBI).
Although the transplantation of unseparated
PBSCs and BMCs containing similar numbers of
-kit cells again led to lower levels of chimerism in
he recipients of mPBSCs than in recipients of BMCs,
he overall differences were substantially smaller and
eached statistical signiﬁcance in only certain lineages
nd at certain time points (Figure 2). For instance,
himerism levels at 26 weeks post-HSCT were (shown
s BMCs vs mPBSCs) 36% vs 17% for CD4 cells
P .05), 26% vs 11% for CD8 cells (P .05), 42%
s 31% for B cells (P  not signiﬁcant [NS]), 29% vs
0% for myeloid cells (P  NS), and 17% vs 11% for
K cells (P  NS) (Figure 2A and 2B). Furthermore,
FU assays of donor BMCs and mPBSCs performed
n this experiment demonstrated that 4.5 times as
any colonies grew from BMCs than from mPBSCs
mean of 2 plates, 288 vs 64 CFU-GM/1  105 plated
ells for BMCs vs mPBSCs), suggesting that the actual
ifference in the frequencies of progenitors might be
arger than estimated based on the percentages of
-kit cells.
We hypothesized that the determined percentages
f c-kit cells underestimate the true difference in
rogenitor content. Thus we calculated whether chi-
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2erism levels correlate more closely with the number
f transplanted progenitor cells as estimated by CFU
ssay. Because we transplanted only 3 times as many
PBSCs as BMCs (following the percentages of
-kit cells), but 4.5 times as many colonies grew from
MCs than from mPBSCs, there still may have been
0% more progenitor cells transplanted in the BMC
roup than in the mPBSC group (28,800 progenitor
ells contained in 10  106 BMCs vs 19,200 progen-
tor cells in 30  106 mPBSCs). Consistent with this
ssessment, we found that in BMC recipients, chimer-
sm levels were 49% higher in CD4 cells, 40%
igher in CD8 cells, and 57% higher in B cells (in
PL at 29 weeks post-HSCT; results from the 2 best
himeras from each group; Table 3). The differences
n chimerism levels among various lineages in blood
ver time were generally of similar magnitudes.
We thus also calculated levels of measured chi-
erism in relation to the estimated number of pro-
enitor cells transplanted (according to CFU results;
etails of the calculation given in Methods); the results
re shown in Figure 3. Levels of donor chimerism per
 104 transplanted progenitors determined in this
ay were very similar for recipients of BMCs and
ecipients of mPBSCs (Figure 3). Higher levels of
-cell chimerism detected among the mPBSC recip-
ents during the ﬁrst few weeks after HSCT were
ikely due to the higher percentage of CD4 and
D8 cells contained in mPBSCs.
Thus the lower levels of multilineage chimerism
able 1. Chimerism Levels in BM and Spleen Correlated With Chime
CD4
: 2 Gy TBI
20  106 BMCs
Mean % of donor cells in BM —
Mean % of donor cells in SPL 65.4
20  106 mPBSCs
Mean % of donor cells in BM —
Mean % of donor cells in SPL 29.1
I: 1 Gy TBI
20  106 BMCs
Mean % of donor cells in BM —
Mean % of donor cells in SPL 28.6
20  106 mPBSCs
Mean % of donor cells in BM —
Mean % of donor cells in SPL 6.3
himerism was analyzed by FCM in BM and spleen (SPL) of recip
TBI (33 weeks posttransplant). Chimerism levels in BM and SP
mice per group were analyzed.
able 2. FCM Analysis of Various Lineage Markers Among BMCs an
Cell Marker CD4 CD8 B220
in BM 1.9 1.8 27.8
in mPBSC 16.8 11.7 38.5
PBSCs contain markedly more CD4 and CD8 cells. Almost 3
One representative result of two similar experiments is shown.
88mong recipients of unseparated mPBSCs compared
ith recipients of BMCs correlate with a lower num-
er of progenitor cells contained in transplanted un-
eparated mPBSCs. On a per-cell basis, progenitor
ells from mPBSCs and BMCs seem to have very
imilar engraftment potential under nonmyeloablative
onditions, leading to similar levels of long-lasting
ultilinear macrochimerism.
hort-Course Immunosuppression Does Not
ignificantly Improve Engraftment
Although CD45-congenic strain combinations are
requently thought of as essentially syngeneic systems
hat allow the tracking of donor cells, it has been
ecognized that CD45 isoforms can elicit immune
esponses [28]. Furthermore, the possibility that mi-
or transplantation antigen differences between the
ecipient and donor strains develop over time due to
pontaneous mutations during breeding cannot be
uled out. Consequently, we explored the possibility
hat the lower levels of mPBSC chimerism were due
o an increased alloresponse compared with that elic-
ted by BMC. We thus treated recipients with a com-
ination of immunosuppressive drugs (rapamycin,
ycophenolate mofetil, and methylprednisolone,
rom day 0 to day 27), which has been shown to
ffectively increase engraftment of allogeneic BMCs
n combination with costimulation blockade [26,29].
s shown in Figure 2, transient immunosuppression
IS) did not signiﬁcantly affect chimerism rates or
vels in Blood After BMT or mPBSCT
B220 MAC1 NK 1.1
78.7 78.0 —
86.2 81.0 45.9
39.7 41.9 —
46.7 48.8 23.1
41.5 43.6 —
48.1 39.3 22.5
12.5 11.7 —
12.9 10.5 5.4
ransplanted with 20  106 BMCs or mPBSCs under 2 or 1 Gy of
lated with chimerism in peripheral blood. Two randomly selected
Cs
MAC1 CD117 CD49b TCR-
64.5 11.1 11.9 4.9
32.3 3.7 33.8 31.6
s many c-kit (CD117) cells are found in BMCs than in mPBSCs.rism Le
CD8
—
58.4
—
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—
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—
5.0
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Nonmyeloablative Transplantation of Congenic PBSCs
Bevels after either BMT or mPBSC transplantation.
ith 1.5-Gy TBI, after mPBSC transplantation, chi-
erism developed in 4 of 4 mice treated with IS versus
of 6 mice without, and after BMT transplantation,
himerism developed in 5 of 5 mice with IS and in 5
f 5 without. Chimerism levels were similar between
he groups with and without IS for the 26-week ob-
ervation period. At the end of follow-up, the mean
ercentage of donor chimerism in peripheral blood of
MC recipients was (with IS vs without IS) 36%
ersus 36% for CD4 cells, 26% versus 26% for
D8 cells, 42% versus 50% for B cells, 29% versus
5% for myeloid cells, and 17% versus 26% for NK
ells, and that of mPBSC recipients was 17% versus
0% for CD4 cells, 11% versus 13% for CD8 cells,
1% versus 32% for B cells, 20% versus 19% for
yeloid cells, and 11% versus 11% for NK cells.
Because additional IS did not signiﬁcantly improve
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igure 2. Transplantation of similar numbers of c-kit mPBSCs
nd c-kit BMCs still led to differences in chimerism levels.
D45.1 mice (n  6/group) received either 10  106 CD45.2
MCs (A, C) or 30  106 CD45.2 mPBSCs (B, D) with 1.5 Gy of
BI. In this manner, similar numbers of c-kit cells were trans-
lanted in both groups (according to the percentage of c-kit cells
s determined by FCM analysis among unseparated mPBSCs and
MCs). To evaluate whether the lower chimerism induced in mPB-
CT recipients is due to a remaining alloresponse against CD45.2,
r to other antigenic differences, some groups received immuno-
uppression (C, D) (rapa, MP, and MMF for four weeks), others
emained untreated (A, B). Chimerism levels in various lineages as
etermined by FCM analysis over time are shown as means. *P 
05 indicates a signiﬁcant difference in chimerism between the
MT and mPBSC transplantation groups (A vs B and C vs D). IS
reatment did not signiﬁcantly improve levels of chimerism (PNS
n any lineage) by either BMT or mPBSC transplantation (A vs C or
vs D). HSCT denotes hematopoietic stem cell transplantation.himerism, the reduced engraftment of mPBSCs is most t
B&MTikely not due to an alloresponse against CD45 or other
utative antigenic strain differences.
ISCUSSION
Although tolerance induction through mixed chi-
erism has been investigated for many years, its trans-
ation into the routine clinical practice of organ trans-
lantation has not yet been achieved [1]. A recent pilot
rial of transplanting kidney and BM grafts simulta-
eously from the same donor to HLA-identical recip-
ents suffering from end-stage kidney failure and mul-
iple myeloma has provided proof of principle that
olerance can indeed be achieved with this approach
30]. At the same time, application of this protocol to
atients without concomitant malignancy might be
roblematic. Substantially milder BMT protocols are
eeded to facilitate widespread use of this tolerance strat-
gy. The clinically unattainable number of required do-
or BMCs is one reason why the mildest regimens
eveloped in murine studies have not been translated
o the clinic so far [6-9,31]. The use of mPBSCs would
llow transplantation of substantially higher numbers
f hematopoietic cells from a single donor, thus po-
entially permitting the application of milder regi-
ens. We thus began to investigate whether mPBSCs
ould be substituted for BMC in costimulation block-
de-based mixed chimerism protocols designed for the
nduction of transplantation tolerance.
As a ﬁrst step toward developing murine mPBSC-
ased tolerance regimens, we investigated the engraft-
ent of unseparated murine mPBSCs in the absence
f alloreactivity. To the best of our knowledge, the
ransplantation of murine mPBSCs after low-dose
onmyeloablative TBI has not yet been investigated in
etail; most previous studies used lethal conditioning
f the recipient [17-24]. Our results demonstrate that
ufﬁcient numbers of HSCs are contained in 20  106
PBSCs to allow successful engraftment and lasting
econstitution under nonmyeloablative conditions, as
videnced by multilineage macrochimerism remaining
table for more than 6 months. As expected, chimer-
sm levels correlated with the dose of irradiation. No-
ably, at all tested TBI doses and in all tested lineages,
himerism induced with mPBSCs was lower than that
chieved with the same number of BMCs. This dif-
erence correlates with the lower percentage of c-kit
ells and CFU-generating cells contained in mPBSCs.
ur data suggest that murine BMCs contain approxi-
ately 3–4 times as many progenitors as mPBSCs, con-
istent with data of Glass et al. [20] showing approxi-
ately 4 times as many CFU-GMs in BMCs than in
PBSCs of DBA/2 mice. Likewise, the percentage of
D34 cells is higher in human BMCs than in human
PBSCs [32]. Thus, under nonmyeloablative condi-ions, murine progenitor cells contained in either mPB-
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2Cs or BMCs have similar engraftment characteristics,
eading to comparable multilineage macrochimerism.
Our results can serve as a rough indicator for the
aximum possible chimerism levels that can ideally be
xpected after transplantation of a given number of
nseparated murine allogeneic mPBSCs if alloreactiv-
able 3. Chimerism Levels in BM and Spleen Correlated With Chime
CD4
: 1.5 Gy TBI
10  106 BMC
Mean % of donor cells in BM —
Mean % of donor cells in SPL 47.2
Mean % of donor cells in THY —
30  106 mPBSC
Mean % of donor cells in BM —
Mean % of donor cells in SPL 31.6
Mean % of donor cells in THY —
I: 1.5 Gy TBI, IS
10  106 BMC
Mean % of donor cells in BM —
Mean % of donor cells in SPL 37.9
Mean % of donor cells in THY —
30  106 mPBSC
Mean % of donor cells in BM —
Mean % of donor cells in SPL 26.1
Mean % of donor cells in THY —
himerism was determined by FCM in BM, spleen (SPL), and thym
or 30 106 mPBSCs after 1.5 Gy of TBI, with IS (II) or without
recipients of BMCs and recipients of mPBSCs were found in th
best chimeras were analyzed per group.
% donor cells per 1x
weeks
after  CD4    CD8
HSCT  A  vs.  B   A  vs. B
1 0.0  vs.  3.8*    0.0  vs.  3.5
3 0.0  vs.  1.7* 0.0  vs.  2.1
4 0.5  vs.  1.6* 0.1  vs.  2.5
8 5.6  vs.  2.4* 3.6  vs.  2.2
15 8.7  vs.  6.6   5.8  vs.  4.7
20 9.9  vs.  7.4   6.9  vs.  4.5
26 12.4  vs.  8.7 8.9  vs.  5.8
*p<0.05
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! p=n.s. in all lineages (A vs. B)
C)
igure 3. Levels of chimerism induced in BMC and mPBSC recipients
FU assays. Chimerism per transplanted progenitor cell was calculat
ercentage of chimerism per 1 104 transplanted progenitor cells, bet
eeks after HSCT (C), probably due to the larger percentage of CD4
ent for which results are also shown in Figure 3. HSCT denotes hematopo
90ty is completely overcome. According to our data,
4.5 times as many murine mPBSCs as BMCs would
ave to be transplanted to achieve similar chimerism.
n the clinic, the cell yield of a mPBSC collection is
ypically 5- to 10-fold greater than that from a con-
entional BM harvest. Thus, although substantially
vels in Blood After BMT or mPBSC Transplantation
8 B220 MAC1 TCR-
37.8 43.9 —
5 54.3 — —
7 — — 69.0
32.3 32.5 —
1 34.5 — —
4 — — 61.1
55.9 48.2 —
9 51.7 — —
7 — — 57.4
36.9 23.8 —
8 45.4 — —
4 — — 41.3
Y) of recipients undergoing transplantation with 10  106 BMCs
29 weeks posttransplant). Similar differences in chimerism between
ues as in blood. IS did not signiﬁcantly inﬂuence chimerism. Two
splanted progenitor cells
B220 MAC-1    NK 1.1
 vs. B A  vs. B  A vs.  B
 vs.  2.7* 0.3  vs.  0.3 0.3 vs.  1.5*
 vs.  1.5* 3.7  vs.  1.6* 1.9 vs.  1.6
 vs.  2.4* 6.0  vs.  3.5* 3.7 vs.  3.0
  vs.  6.1* 9.3  vs.  7.7   5.9 vs.  5.1
  vs.11.6   9.9  vs.  7.3   6.3 vs.  4.1
  vs.11.5    10.8  vs.  9.1   7.1 vs.  6.5
  vs.16.1 9.9  vs.10.5 5.9 vs.  5.7
4 8 12 16 20 24 28
B) mPBSC recipients
 1.5Gy TBI, NO IS
SCT
MAC1 NK 1.1
!   !   ! 
ted with the number of transplanted progenitor cells as estimated from
escribed in detail in the Methods section. A signiﬁcant difference in
MC and mPBSC recipients (A vs B) is noticeable only in the ﬁrst few
CD8 cells contained in mPBSC. Data are from the same experi-rism Le
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Nonmyeloablative Transplantation of Congenic PBSCs
Bigher chimerism levels can be expected from trans-
lantation of an mPBSC harvest, these results raise
oubts as to whether the advantage of harvesting mPB-
Cs is great enough to make mPBSCs a viable source of
ufﬁcient donor hematopoietic cells to induce chimerism
ithout cytoreduction [6,29]. This question is currently
eing addressed in our laboratory.
One caveat that must be considered when at-
empting to extrapolate these results from a syngeneic
odel to tolerance protocols pertains to the role of
onor T cells in promoting engraftment in the allo-
eneic setting. Theoretically, mPBSCs, which are en-
iched for T cells, might lead to better engraftment
hen transplanted across an allogeneic barrier.
The CD45.1 isoform may induce a weak T-cell–
ediated immune response [28] that is nonetheless
trong enough to reduce BM engraftment [33]. This
mmunogenicity is of concern, especially when mini-
al recipient conditioning leaves the host immune
ystem largely intact. Even though signiﬁcant immu-
ogenicity was not found in the (reverse) strain com-
ination that we used (CD45.2 into CD45.1) [34,35],
e nevertheless wanted to rule out that mPBSCs elicit
stronger immune response against CD45.2 than
MCs, or any other minor antigenic differences be-
ween the donor and recipient strains. We thus treated
ecipients with a combination of immunosuppressive
rugs that promotes chimerism in allogeneic models
26,29]. IS did not detectably increase engraftment, in-
icating that alloreactivity is not responsible for the
ower chimerism achieved with mPBSCs in our studies.
mPBSCs have already been used in a limited num-
er of large-animal models to induce chimerism and
olerance [36-38]. In a haploidentical swine model, for
nstance, transplantation of megadoses of mPBSCs
fter thymic irradiation and recipient T-cell depletion
ed to long-term chimerism and tolerance. Although
ubstantial levels of chimerism were achieved, it re-
ains unclear how the engraftment potential of swine
PBSCs compares with that of BMCs, because no
irect comparison is available within the same model.
or numerous reasons, large-animal models of toler-
nce generally are less successful and require more
ntense protocols than murine models. These regi-
ens are usually developed in mice using BMCs, but
ot mPBSCs [39]. Nonetheless, it has not been con-
incingly shown that allogeneic mPBSCs behave sufﬁ-
iently similarly to allow substitution without requiring
odiﬁcation of the protocols. Given the numerous
nown immunologic differences between BMCs and
PBSCs [12-16], it appears likely that their properties
ssociated with the ability to induce tolerance may
iffer. This is of particular concern when costimula-
ion blockers are used in combination with HSCT,
ecause these blockers’ mechanisms of action depend
ritically on the details of a speciﬁc experimental pro-
ocol. Based on the results of the congenic models
B&MTresented herein, studies are currently under way in
ur laboratory to develop costimulation-based alloge-
eic murine PBSC protocols.
From the present study, we conclude that in the
bsence of alloreactivity, transplantation of unsepa-
ated murine mPBSCs effectively leads to stable, long-
erm multilineage chimerism. However, due to the
ower frequency of progenitor cells, mPBSCs induce
ower chimerism levels than the same number of un-
eparated BMCs. A typical mPBSC harvest in the
linic yields 5-10 times as many hematopoietic cells as
BM harvest [40,41], however, more than offsetting
his difference and allowing the transplantation of
ore HSCs. Thus, because our data show that very
imilar chimerism levels can be expected per trans-
lanted progenitor, they support the evaluation of
llogeneic mPBSCs for the purpose of developing
linically more relevant mixed-chimerism models.
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